Evolutionary Origin of MUTYH Germline Pathogenic Variations in Modern Humans

Biomolecules. 2023 Feb 24;13(3):429. doi: 10.3390/biom13030429.

Abstract

MUTYH plays an essential role in preventing oxidation-caused DNA damage. Pathogenic germline variations in MUTYH damage its function, causing intestinal polyposis and colorectal cancer. Determination of the evolutionary origin of the variation is essential to understanding the etiological relationship between MUTYH variation and cancer development. In this study, we analyzed the origins of pathogenic germline variants in human MUTYH. Using a phylogenic approach, we searched MUTYH pathogenic variants in modern humans in the MUTYH of 99 vertebrates across eight clades. We did not find pathogenic variants shared between modern humans and the non-human vertebrates following the evolutionary tree, ruling out the possibility of cross-species conservation as the origin of human pathogenic variants in MUTYH. We then searched the variants in the MUTYH of 5031 ancient humans and extinct Neanderthals and Denisovans. We identified 24 pathogenic variants in 42 ancient humans dated between 30,570 and 480 years before present (BP), and three pathogenic variants in Neanderthals dated between 65,000 and 38,310 years BP. Data from our study revealed that human MUTYH pathogenic variants mostly arose in recent human history and partially originated from Neanderthals.

Keywords: MUTYH; ancient humans; archaeological; evolutionary origin; pathogenic variant; phylogenic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenomatous Polyposis Coli* / genetics
  • Adenomatous Polyposis Coli* / pathology
  • Animals
  • Colorectal Neoplasms* / genetics
  • Genetic Predisposition to Disease
  • Germ Cells
  • Germ-Line Mutation
  • Humans
  • Mutation
  • Neanderthals* / genetics
  • Oxidative Stress

Substances

  • mutY adenine glycosylase

Grants and funding

This research was funded by the Macau Science and Technology Development Fund (No. 085/2017/A2, 0077/2019/AMJ, 0032/2022/A1), the University of Macau Fund (No. SRG2017-00097-FHS, MYRG2019-00018-FHS, 2020-00094-FHS) and the Faculty of Health Sciences, University of Macau (No. FHSIG/SW/0007/2020P, MOE Frontiers Science Center for Precision Oncology pilot grant, and a startup fund) to S.M.W.